Potential role of HE4 in multimodal screening for epithelial ovarian cancer

Journal of the National Cancer Institute

Volumn 103, Issue 21, 2011, Pages 1630-1634

  Urban, Nicole ^a   Thorpe, Jason D ^a   Bergan, Lindsay A ^a   Forrest, Robin M ^a   Kampani, Archana V ^a   Scholler, Nathalie ^b   O'Briant, Kathy C ^a   Anderson, Garnet L ^a   Cramer, Daniel W ^c   Berg, Christine D ^d   McIntosh, Martin W ^a   Hartge, Patricia ^d   Drescher, Charles W ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MATRILYSIN; MESOTHELIN; SOMATOMEDIN BINDING PROTEIN 2; THROMBOSPONDIN 2;

ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; ENDOMETRIOSIS; FOLLOW UP; HUMAN; HYSTERECTOMY; INTERMETHOD COMPARISON; NULLIPARA; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMOKING; TRANSVAGINAL ECHOGRAPHY;

ADULT; AGED; AGING; CA-125 ANTIGEN; CARCINOMA; CASE-CONTROL STUDIES; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY; VAGINA;

EID: 80655128171     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr359     Document Type: Article

References (16)

1. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775-782.
2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-2303.
3. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-340.
4. Palmer C, Duan X, Hawley S, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 2008;3(7):e2633.
5. Simon I, Liu Y, Krall KL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106(1):112-118. (Pubitemid 46898578)
6. Havrilesky LJ, Whitehead CM, Rubatt JM. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374-382.
7. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006;16(5):1733-1745. (Pubitemid 44470029)
8. Anderson GL, McIntosh MW, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102(1):26-38.
9. Cramer DW, Bast RCJr, Berg CD. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res (Phila). 2011;4(3):365-374.
10. Zhu CS, Pinsky PF, Cramer DW, et al.; for the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4(3):375-383.
11. McIntosh M, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev. 2002;11(2):159-166. (Pubitemid 34202997)
12. McIntosh M, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003;4(1):27-40. (Pubitemid 36116886)
13. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2480-2487.
14. Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol. 2008;110(3):383-389.
15. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-443.
16. DePriest PD, Varner E, Powell J, et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol. 1994;55(2):174-178. (Pubitemid 24366622)